Symbols / ANIX Stock $2.62 -4.38% Anixa Biosciences, Inc.
ANIX (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Official websiteAnixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged in the development of a vaccine against breast cancer; and the development of a vaccine discovery program to develop additional cancer vaccines to address intractable cancers, including high incidence malignancies in lung, colon, and prostate. Its vaccine technologies focus on the discovery of additional retired proteins that may be associated with other forms of cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
Ratings
Current target
$2.62
Low
$7.00
High
$14.00
Mean
$10.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-04-08 | main | D. Boral Capital | Buy → Buy | $10 |
| 2026-03-31 | main | D. Boral Capital | Buy → Buy | $10 |
| 2026-02-04 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-12-12 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-10-07 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-09-22 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-09-11 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2025-09-09 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-08-19 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-08-05 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-06-10 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-05-29 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-04-10 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-03-26 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-03-25 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2025-03-21 | init | Maxim Group | — → Buy | $10 |
| 2025-02-18 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2025-01-22 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-01-14 | main | D. Boral Capital | Buy → Buy | $10 |
| 2024-11-19 | main | D. Boral Capital | Buy → Buy | $10 |
- META_TITLE_QUOTE - Yahoo Finance hu, 25 Jun 2026 15
- Here's Why You Should Add ANIX Stock to Your Portfolio Now - Zacks Investment Research hu, 25 Jun 2026 14
- Here's Why You Should Add ANIX Stock to Your Portfolio Now - Yahoo Finance Australia hu, 25 Jun 2026 14
- ANIXA BIOSCIENCES INC (ANIX) Stock Chart - ChartMill Fri, 19 Jun 2026 00
- Anixa Biosciences (NASDAQ: ANIX) CEO adds 21,000 shares - Stock Titan ue, 16 Jun 2026 07
- Insider Purchase: Chief Executive Officer of $ANIX Buys 21,000 Shares - Quiver Quantitative ue, 16 Jun 2026 07
- Anixa Biosciences Announces Issuance of Mexican Patent Covering Breast Cancer Vaccine Technology - PR Newswire Wed, 29 Apr 2026 07
- Insider Purchase: Chief Executive Officer of $ANIX Buys 21,000 Shares - Moomoo ue, 16 Jun 2026 13
- Anixa Biosciences Inc (ANIX) Valuation: PE, PB & Fair Value Analysis - TradingKey Wed, 24 Jun 2026 07
- Bloomberg TV to air Anixa CEO on cancer vaccine and CAR-T data - Stock Titan Fri, 01 May 2026 07
- Anixa Biosciences Interview to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV - PR Newswire Fri, 01 May 2026 07
- Here's Why We're Not Too Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Situation - Yahoo Finance Sun, 08 Feb 2026 08
- Anixa Biosciences (ANIX) director adds 2,836 shares in open-market buy - Stock Titan Wed, 17 Jun 2026 15
- $ANIX stock is up 19% today. Here's what we see in our data. - Quiver Quantitative ue, 07 Oct 2025 07
- Breast cancer vaccine triggers immune response in 74% of participants - Stock Titan hu, 11 Jun 2026 07
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
-100.00%
|
0.21
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
-100.00%
|
0.21
|
0.00
|
| Cost Of Revenue |
|
—
|
0.00
-100.00%
|
0.16
|
0.00
|
| Reconciled Cost Of Revenue |
|
—
|
0.00
-100.00%
|
0.16
|
0.00
|
| Gross Profit |
|
—
|
0.00
-100.00%
|
0.05
|
0.00
|
| Operating Expense |
|
11.70
-15.40%
|
13.83
+25.05%
|
11.06
-20.29%
|
13.88
|
| Research And Development |
|
5.07
-20.72%
|
6.40
+34.12%
|
4.77
-28.85%
|
6.70
|
| Selling General And Administration |
|
6.63
-10.83%
|
7.43
+18.18%
|
6.29
-12.28%
|
7.17
|
| General And Administrative Expense |
|
6.63
-10.83%
|
7.43
+18.18%
|
6.29
-12.28%
|
7.17
|
| Other Gand A |
|
6.63
-10.83%
|
7.43
+18.18%
|
6.29
-12.28%
|
7.17
|
| Total Expenses |
|
11.70
-15.40%
|
13.83
+23.26%
|
11.22
-19.13%
|
13.88
|
| Operating Income |
|
-11.70
+15.40%
|
-13.83
-25.61%
|
-11.01
+20.64%
|
-13.88
|
| Total Operating Income As Reported |
|
-11.70
+15.40%
|
-13.83
-25.61%
|
-11.01
+20.64%
|
-13.88
|
| EBITDA |
|
-11.66
+15.43%
|
-13.79
-25.80%
|
-10.96
+20.73%
|
-13.83
|
| Normalized EBITDA |
|
-11.66
+15.43%
|
-13.79
-25.80%
|
-10.96
+20.73%
|
-13.83
|
| Reconciled Depreciation |
|
0.04
-2.70%
|
0.04
-19.57%
|
0.05
+9.52%
|
0.04
|
| EBIT |
|
-11.70
+15.40%
|
-13.83
-25.61%
|
-11.01
+20.64%
|
-13.88
|
| Total Unusual Items |
|
—
|
—
|
—
|
0.00
|
| Total Unusual Items Excluding Goodwill |
|
—
|
—
|
—
|
0.00
|
| Special Income Charges |
|
—
|
—
|
—
|
0.00
|
| Net Income |
|
-10.93
+12.96%
|
-12.55
-27.96%
|
-9.81
+27.83%
|
-13.60
|
| Pretax Income |
|
-11.03
+13.15%
|
-12.70
-27.88%
|
-9.93
+27.89%
|
-13.77
|
| Net Non Operating Interest Income Expense |
|
0.67
-40.60%
|
1.13
+4.81%
|
1.08
+939.42%
|
0.10
|
| Net Interest Income |
|
0.67
-40.60%
|
1.13
+4.81%
|
1.08
+939.42%
|
0.10
|
| Interest Income Non Operating |
|
0.67
-40.60%
|
1.13
+4.81%
|
1.08
+939.42%
|
0.10
|
| Interest Income |
|
0.67
-40.60%
|
1.13
+4.81%
|
1.08
+939.42%
|
0.10
|
| Other Income Expense |
|
—
|
—
|
—
|
—
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-11.03
+13.15%
|
-12.70
-27.88%
|
-9.93
+27.89%
|
-13.77
|
| Net Income From Continuing Operation Net Minority Interest |
|
-10.93
+12.96%
|
-12.55
-27.96%
|
-9.81
+27.83%
|
-13.60
|
| Net Income From Continuing And Discontinued Operation |
|
-10.93
+12.96%
|
-12.55
-27.96%
|
-9.81
+27.83%
|
-13.60
|
| Net Income Continuous Operations |
|
-11.03
+13.15%
|
-12.70
-27.88%
|
-9.93
+27.89%
|
-13.77
|
| Minority Interests |
|
0.10
-29.86%
|
0.14
+21.01%
|
0.12
-32.39%
|
0.18
|
| Normalized Income |
|
-10.93
+12.96%
|
-12.55
-27.96%
|
-9.81
+27.83%
|
-13.60
|
| Net Income Common Stockholders |
|
-10.93
+12.96%
|
-12.55
-27.96%
|
-9.81
+27.83%
|
-13.60
|
| Diluted EPS |
|
-0.34
+12.82%
|
-0.39
-21.88%
|
-0.32
+28.89%
|
-0.45
|
| Basic EPS |
|
-0.34
+12.82%
|
-0.39
-21.88%
|
-0.32
+28.89%
|
-0.45
|
| Basic Average Shares |
|
32.45
+1.74%
|
31.90
+2.96%
|
30.98
+2.00%
|
30.37
|
| Diluted Average Shares |
|
32.45
+1.74%
|
31.90
+2.96%
|
30.98
+2.00%
|
30.37
|
| Diluted NI Availto Com Stockholders |
|
-10.93
+12.96%
|
-12.55
-27.96%
|
-9.81
+27.83%
|
-13.60
|
| Gain On Sale Of PPE |
|
—
|
—
|
—
|
0.00
|
| Line Item | Trend | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|---|
| Total Assets |
|
16.08
-25.52%
|
21.59
-15.40%
|
25.52
-16.08%
|
30.41
|
| Current Assets |
|
15.89
-25.63%
|
21.36
-15.75%
|
25.36
-16.04%
|
30.20
|
| Cash Cash Equivalents And Short Term Investments |
|
15.17
-23.84%
|
19.92
-16.44%
|
23.84
-19.68%
|
29.69
|
| Cash And Cash Equivalents |
|
1.24
-2.12%
|
1.27
+38.91%
|
0.92
-92.60%
|
12.36
|
| Other Short Term Investments |
|
13.93
-25.32%
|
18.65
-18.65%
|
22.93
+32.33%
|
17.33
|
| Receivables |
|
0.00
-100.00%
|
0.17
-35.93%
|
0.27
+486.96%
|
0.05
|
| Accounts Receivable |
|
0.00
-100.00%
|
0.17
-35.93%
|
0.27
+486.96%
|
0.05
|
| Prepaid Assets |
|
—
|
—
|
—
|
0.51
|
| Other Current Assets |
|
0.71
-43.64%
|
1.26
+1.85%
|
1.24
+165.95%
|
0.47
|
| Total Non Current Assets |
|
0.19
-15.72%
|
0.23
+37.95%
|
0.17
-21.70%
|
0.21
|
| Net PPE |
|
0.19
-15.72%
|
0.23
+37.95%
|
0.17
-21.70%
|
0.21
|
| Gross PPE |
|
0.19
-15.72%
|
0.23
+37.95%
|
0.17
-21.70%
|
0.21
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Buildings And Improvements |
|
0.19
-15.72%
|
0.23
+37.95%
|
0.17
-21.70%
|
0.21
|
| Other Properties |
|
0.19
-15.72%
|
0.23
+37.95%
|
0.17
-21.70%
|
0.21
|
| Leases |
|
0.19
-15.72%
|
0.23
+37.95%
|
0.17
-21.70%
|
0.21
|
| Total Liabilities Net Minority Interest |
|
2.13
-21.20%
|
2.70
+25.66%
|
2.15
-2.76%
|
2.21
|
| Current Liabilities |
|
1.97
-21.32%
|
2.50
+23.27%
|
2.03
-0.44%
|
2.04
|
| Payables And Accrued Expenses |
|
1.93
-22.06%
|
2.47
+25.05%
|
1.98
-0.75%
|
1.99
|
| Payables |
|
0.17
-68.57%
|
0.53
+154.85%
|
0.21
-22.26%
|
0.27
|
| Accounts Payable |
|
0.17
-68.57%
|
0.53
+154.85%
|
0.21
-22.26%
|
0.27
|
| Current Accrued Expenses |
|
1.76
-9.51%
|
1.95
+9.94%
|
1.77
+2.55%
|
1.73
|
| Current Debt And Capital Lease Obligation |
|
0.04
+41.38%
|
0.03
-44.23%
|
0.05
+13.04%
|
0.05
|
| Current Capital Lease Obligation |
|
0.04
+41.38%
|
0.03
-44.23%
|
0.05
+13.04%
|
0.05
|
| Total Non Current Liabilities Net Minority Interest |
|
0.16
-19.70%
|
0.20
+65.04%
|
0.12
-29.71%
|
0.17
|
| Long Term Debt And Capital Lease Obligation |
|
0.16
-19.70%
|
0.20
+65.04%
|
0.12
-29.71%
|
0.17
|
| Long Term Capital Lease Obligation |
|
0.16
-19.70%
|
0.20
+65.04%
|
0.12
-29.71%
|
0.17
|
| Stockholders Equity |
|
15.16
-24.19%
|
20.00
-17.83%
|
24.34
-16.22%
|
29.05
|
| Common Stock Equity |
|
15.16
-24.19%
|
20.00
-17.83%
|
24.34
-16.22%
|
29.05
|
| Capital Stock |
|
0.33
+2.48%
|
0.32
+3.54%
|
0.31
+0.65%
|
0.31
|
| Common Stock |
|
0.33
+2.48%
|
0.32
+3.54%
|
0.31
+0.65%
|
0.31
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
33.01
+2.54%
|
32.20
+3.38%
|
31.15
+0.75%
|
30.91
|
| Ordinary Shares Number |
|
33.01
+2.54%
|
32.20
+3.38%
|
31.15
+0.75%
|
30.91
|
| Additional Paid In Capital |
|
266.51
+2.33%
|
260.43
+3.26%
|
252.22
+2.06%
|
247.12
|
| Retained Earnings |
|
-251.68
-4.54%
|
-240.75
-5.50%
|
-228.20
-4.49%
|
-218.38
|
| Treasury Stock |
|
0.00
-100.00%
|
0.01
|
0.00
|
—
|
| Minority Interest |
|
-1.21
-9.10%
|
-1.11
-14.91%
|
-0.97
-14.05%
|
-0.85
|
| Total Equity Gross Minority Interest |
|
13.95
-26.14%
|
18.89
-19.18%
|
23.37
-17.12%
|
28.20
|
| Total Capitalization |
|
15.16
-24.19%
|
20.00
-17.83%
|
24.34
-16.22%
|
29.05
|
| Working Capital |
|
13.92
-26.20%
|
18.86
-19.14%
|
23.33
-17.17%
|
28.16
|
| Invested Capital |
|
15.16
-24.19%
|
20.00
-17.83%
|
24.34
-16.22%
|
29.05
|
| Total Debt |
|
0.20
-12.07%
|
0.23
+32.57%
|
0.17
-20.81%
|
0.22
|
| Capital Lease Obligations |
|
0.20
-12.07%
|
0.23
+32.57%
|
0.17
-20.81%
|
0.22
|
| Net Tangible Assets |
|
15.16
-24.19%
|
20.00
-17.83%
|
24.34
-16.22%
|
29.05
|
| Tangible Book Value |
|
15.16
-24.19%
|
20.00
-17.83%
|
24.34
-16.22%
|
29.05
|
| Line Item | Trend | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-7.17
+2.21%
|
-7.33
-18.13%
|
-6.21
+4.36%
|
-6.49
|
| Cash Flow From Continuing Operating Activities |
|
-7.17
+2.21%
|
-7.33
-18.13%
|
-6.21
+4.36%
|
-6.49
|
| Net Income From Continuing Operations |
|
-11.03
+13.15%
|
-12.70
-27.88%
|
-9.93
+27.89%
|
-13.77
|
| Depreciation Amortization Depletion |
|
0.04
-2.70%
|
0.04
-19.57%
|
0.05
+9.52%
|
0.04
|
| Depreciation |
|
0.04
-2.70%
|
0.04
-19.57%
|
0.05
+9.52%
|
0.04
|
| Depreciation And Amortization |
|
0.04
-2.70%
|
0.04
-19.57%
|
0.05
+9.52%
|
0.04
|
| Other Non Cash Items |
|
0.13
-66.05%
|
0.38
+21.41%
|
0.31
-58.38%
|
0.75
|
| Stock Based Compensation |
|
3.68
-16.72%
|
4.42
-0.05%
|
4.42
-26.30%
|
6.00
|
| Operating Gains Losses |
|
—
|
—
|
—
|
—
|
| Gain Loss On Sale Of PPE |
|
—
|
—
|
—
|
0.00
|
| Change In Working Capital |
|
0.15
-71.10%
|
0.53
+149.62%
|
-1.06
-318.56%
|
0.48
|
| Change In Receivables |
|
0.17
+78.35%
|
0.10
+143.30%
|
-0.22
-672.41%
|
-0.03
|
| Change In Prepaid Assets |
|
0.55
+2500.00%
|
-0.02
+97.03%
|
-0.78
-272.60%
|
-0.21
|
| Change In Payables And Accrued Expense |
|
-0.55
-210.10%
|
0.49
+3400.00%
|
-0.01
-101.97%
|
0.76
|
| Change In Accrued Expense |
|
-0.18
-205.11%
|
0.18
+300.00%
|
0.04
-93.03%
|
0.63
|
| Change In Payable |
|
-0.36
-212.85%
|
0.32
+640.68%
|
-0.06
-145.74%
|
0.13
|
| Change In Account Payable |
|
-0.36
-212.85%
|
0.32
+640.68%
|
-0.06
-145.74%
|
0.13
|
| Change In Other Working Capital |
|
—
|
—
|
—
|
—
|
| Change In Other Current Liabilities |
|
-0.03
+34.88%
|
-0.04
+6.52%
|
-0.05
-21.05%
|
-0.04
|
| Investing Cash Flow |
|
4.87
+13.80%
|
4.28
+176.33%
|
-5.60
+47.78%
|
-10.73
|
| Cash Flow From Continuing Investing Activities |
|
4.87
+13.80%
|
4.28
+176.33%
|
-5.60
+47.78%
|
-10.73
|
| Net PPE Purchase And Sale |
|
—
|
—
|
—
|
0.00
|
| Purchase Of PPE |
|
—
|
—
|
—
|
—
|
| Sale Of PPE |
|
—
|
—
|
—
|
0.00
|
| Net Investment Purchase And Sale |
|
4.87
+13.80%
|
4.28
+176.33%
|
-5.60
+47.78%
|
-10.73
|
| Purchase Of Investment |
|
-44.36
+30.44%
|
-63.77
-43.59%
|
-44.41
-97.51%
|
-22.49
|
| Sale Of Investment |
|
49.23
-27.66%
|
68.05
+75.34%
|
38.81
+230.06%
|
11.76
|
| Net Business Purchase And Sale |
|
—
|
—
|
—
|
0.00
|
| Gain Loss On Sale Of Business |
|
—
|
—
|
—
|
—
|
| Financing Cash Flow |
|
2.28
-33.24%
|
3.42
+833.06%
|
0.37
-19.03%
|
0.45
|
| Cash Flow From Continuing Financing Activities |
|
2.28
-33.24%
|
3.42
+833.06%
|
0.37
-19.03%
|
0.45
|
| Net Common Stock Issuance |
|
2.38
-19.36%
|
2.95
|
0.00
|
0.00
|
| Common Stock Payments |
|
0.00
+100.00%
|
-0.01
|
0.00
|
—
|
| Repurchase Of Capital Stock |
|
0.00
+100.00%
|
-0.01
|
0.00
|
—
|
| Proceeds From Stock Option Exercised |
|
-0.10
-121.03%
|
0.47
+27.32%
|
0.37
-19.03%
|
0.45
|
| Changes In Cash |
|
-0.03
-107.58%
|
0.36
+103.11%
|
-11.45
+31.74%
|
-16.77
|
| Beginning Cash Position |
|
1.27
+38.91%
|
0.92
-92.60%
|
12.36
-57.57%
|
29.13
|
| End Cash Position |
|
1.24
-2.12%
|
1.27
+38.91%
|
0.92
-92.60%
|
12.36
|
| Free Cash Flow |
|
-7.17
+2.21%
|
-7.33
-18.13%
|
-6.21
+4.36%
|
-6.49
|
| Amortization Of Securities |
|
-0.14
|
0.00
|
—
|
—
|
| Common Stock Issuance |
|
2.38
-19.53%
|
2.96
|
0.00
|
0.00
|
| Issuance Of Capital Stock |
|
2.38
-19.53%
|
2.96
|
0.00
|
0.00
|
| Sale Of Business |
|
—
|
—
|
—
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-06-17 View
- 42026-06-16 View
- 10-Q2026-06-10 View
- 8-K2026-03-11 View
- 10-Q2026-03-09 View
- 8-K2026-02-09 View
- 42026-01-29 View
- 10-K2026-01-12 View
- 42026-01-06 View
- 42026-01-06 View
- 42026-01-06 View
- 42026-01-06 View
- 42026-01-06 View
- 42025-12-16 View
- 8-K2025-12-12 View
- 42025-10-31 View
- 10-Q2025-09-10 View
- 42025-08-04 View
- 42025-07-31 View
- 42025-07-21 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|